Jonathan Duffy

Jonathan Duffy

Auto-generated profile, based on publicly available information

Jonathan Duffy

Centers for Disease Control and Prevention

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Vaccine
Verified
Journal Article
Closed access
DGDiane Gubernot
Diane Gubernot
AJAmelia Jazwa
Amelia Jazwa
MNManette Niu
Manette Niu
JBJane Baumblatt
Jane Baumblatt
JGJulianne Gee
Julianne Gee
SBSarah Bennett
Sarah Bennett

11 November 2014 in Neurology
Verified
Journal Article
Closed access
PDF file
JDJonathan Duffy
Jonathan Duffy
EWEric Weintraub
Eric Weintraub
CVClaudia Vellozzi
Claudia Vellozzi
FDFrank DeStefano
Frank DeStefano
Objective: To assess the occurrence of narcolepsy after influenza vaccines used in the United States that contained the influenza A(H1N1)pdm09 virus strain. Methods: A population-based cohort study in the Vaccine Safety Datalink with an annual population of more than 8.5 million people. All persons younger than 30 years who received a 2009 pandemic or a 2010–2011 seasonal influenza vaccine were identified. Their medical visit history was searched for a first-ever occurrence of an ICD-9 narcolepsy diagnosis code through the end of 2011. Chart review was done to confirm the diagnosis and determine the date of symptom onset. Cases were patients who met the International Classification of Sleep Disorders, 2nd edition, narcolepsy diagnostic criteria. We compared the observed number of cases after vaccination to the number expected to occur by chance alone. Results: The number vaccinated with 2009 pandemic vaccine was 650,995 and with 2010–2011 seasonal vaccine was 870,530. Among these patients, 70 had a first-ever narcolepsy diagnosis code after vaccination, of which 16 had a chart-confirmed incident diagnosis of narcolepsy. None had their symptom onset during the 180 days after receipt of a 2009 pandemic vaccine compared with 6.52 expected, and 2 had onset after a 2010–2011 seasonal vaccine compared with 8.83 expected. Conclusions: Influenza vaccines containing the A(H1N1)pdm09 virus strain used in the United States were not associated with an increased risk of narcolepsy. Vaccination with the influenza A(H1N1)pdm09 vaccine viral antigens does not appear to be sufficient by itself to increase the incidence of narcolepsy in a population.

1 July 2016 in Pediatrics
Verified
Journal Article
Closed access
PDF file
JDJonathan Duffy
Jonathan Duffy
EWEric Weintraub
Eric Weintraub
SHSimon J. Hambidge
Simon J. Hambidge
LJLisa A. Jackson
Lisa A. Jackson
EKElyse O. Kharbanda
Elyse O. Kharbanda
ODOn Behalf Of The Vaccine Safety Datalink
On Behalf Of The Vaccine Safety Datalink
BACKGROUND AND OBJECTIVE: An increased risk of febrile seizure (FS) was identified with concomitant administration of trivalent inactivated influenza vaccine (IIV3) and pneumococcal conjugate vaccine (PCV) 13-valent during the 2010–2011 influenza season. Our objective was to determine whether concomitant administration of IIV3 with other vaccines affects the FS risk. METHODS: We examined the risk of FS 0 to 1 day postvaccination for all routinely recommended vaccines among children aged 6 through 23 months during a period encompassing 5 influenza seasons (2006–2007 through 2010–2011). We used a population-based self-controlled risk interval analysis with a control interval of 14 to 20 days postvaccination. We used multivariable regression to control for receipt of concomitant vaccines and test for interaction between vaccines. RESULTS: Only PCV 7-valent had an independent FS risk (incidence rate ratio [IRR], 1.98; 95% confidence interval [CI], 1.00 to 3.91). IIV3 had no independent risk (IRR, 0.46; 95% CI, 0.21 to 1.02), but risk was increased when IIV3 was given with either PCV (IRR, 3.50; 95% CI, 1.13 to 10.85) or a diphtheria-tetanus-acellular-pertussis (DTaP)-containing vaccine (IRR, 3.50; 95% CI, 1.52 to 8.07). The maximum estimated absolute excess risk due to concomitant administration of IIV3, PCV, and DTaP-containing vaccines compared with administration on separate days was 30 FS per 100 000 persons vaccinated. CONCLUSIONS: The administration of IIV3 on the same day as either PCV or a DTaP-containing vaccine was associated with a greater risk of FS than when IIV3 was given on a separate day. The absolute risk of postvaccination FS with these vaccine combinations was small.

1 February 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
OZOusseny Zerbo
Ousseny Zerbo
JBJoan Bartlett
Joan Bartlett
BFBruce Fireman
Bruce Fireman
NLNed Lewis
Ned Lewis
KGKristin Goddard
Kristin Goddard
NKNicola P. Klein
Nicola P. Klein
A 2-dose series of recombinant zoster vaccine (RZV) was 97% effective against herpes zoster (HZ) in a pivotal clinical trial. To evaluate real-world effectiveness of RZV against HZ. Prospective cohort study. Four health care systems in the Vaccine Safety Datalink. Persons aged 50 years or older. The outcome was incident HZ defined by a diagnosis with an antiviral prescription. Cox regression was used to estimate the hazard of HZ in vaccinated persons compared with unvaccinated persons, with adjustment for covariates. Vaccine effectiveness (VE) was calculated as 1 minus the adjusted hazard ratio and was estimated by time since the last RZV dose and by corticosteroid use. The study included nearly 2.0 million persons who contributed 7.6 million person-years of follow-up. After adjustment, VE of 1 dose was 64% and VE of 2 doses was 76%. After 1 dose only, VE was 70% during the first year, 45% during the second year, 48% during the third year, and 52% after the third year. After 2 doses, VE was 79% during the first year, 75% during the second year, and 73% during the third and fourth years. Vaccine effectiveness was 65% in persons who received corticosteroids before vaccination and 77% in those who did not. Herpes zoster could not be identified as accurately in these observational data as in the previous clinical trials. Two doses of RZV were highly effective, although less effective than in the previous clinical trials. Two-dose effectiveness waned very little during the 4 years of follow-up. However, 1-dose effectiveness waned substantially after 1 year, underscoring the importance of the second dose. Centers for Disease Control and Prevention.

9 December 2022 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
JDJonathan Duffy
Jonathan Duffy
PMPaige Marquez
Paige Marquez
PMPedro Moro
Pedro Moro
EWEric Weintraub
Eric Weintraub
YYYon Yu
Yon Yu
TSTom Shimabukuro
Tom Shimabukuro
This report describes surveillance that supports the safety of the JYNNEOS vaccine for preventing mpox.

1 April 2016 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
RLRongxia Li
Rongxia Li
BSBrock Stewart
Brock Stewart
MMMichael M. McNeil
Michael M. McNeil
JDJonathan Duffy
Jonathan Duffy
JNJennifer Nelson
Jennifer Nelson
EWEric Weintraub
Eric Weintraub